1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Unknown 1 |
Follow Withdrawal: new trials by email Literature Review of Withdrawal trials Research Report on Withdrawal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis Prednisolone, Sulfasalazine, Leflunomide - Psoriatic Arthritis, Withdrawal | Phase 3 | Unknown | University of Erlangen-Nürnberg Medical School | 270 | 2020-10-19 | 2022-11-14 |
Arthritis (1) · Bone Diseases (1) · Joint Diseases (1) · Musculoskeletal Diseases (1) · Psoriasis (1) · Skin Diseases (1) · Skin Diseases, Papulosquamous (1) · Skin and Connective Tissue Diseases (1) · Spinal Diseases (1) · Spondylarthritis (1) · Spondylarthropathies (1) · Spondylitis (1)
Abatacept (1) · Adalimumab (1) · Certolizumab Pegol (1) · Etanercept (1) · Infliximab (1) · Leflunomide (1) · Methotrexate (1) · Prednisolone (1) · Sulfasalazine (1) · Ustekinumab (1) · apremilast (1) · golimumab (1) · ixekizumab (1) · secukinumab (1) · tofacitinib (1)
University of Erlangen-Nürnberg Medical School (1)
Germany (1)